The company is building ex vivo research and discovery platforms, leveraging expertise in microbiology and artificial intelligence, to analyze the symbiotic relationship between the microbiota and the human intestine. NovoSift is designed to mimic human intestinal physiology and unlock new insights into disease pathophysiology and reveal novel drug targets, compounds, and live biotherapeutic drug candidates.
NovoBiome's first drug candidate, ADC-001, for nonalcoholic fatty liver disease and nonalcoholic steato-hepatitis, is made of an anti-inflammatory bacterium with demonstrated in vitro and preclinical potency. The company aims to begin human clinical trials by 2022-2023.
Copyright © 2021 scienceboard.net